Detalles de la búsqueda
1.
heredERA Breast Cancer: a phase III, randomized, open-label study evaluating the efficacy and safety of giredestrant plus the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with previously untreated HER2-positive, estrogen receptor-positive locally advanced or metastatic breast cancer.
BMC Cancer
; 24(1): 641, 2024 May 24.
Artículo
en Inglés
| MEDLINE | ID: mdl-38789924
2.
A phase 2 study of first-line nivolumab in patients with locally advanced or metastatic cutaneous squamous-cell carcinoma.
Cancer
; 128(24): 4223-4231, 2022 12 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-36274573
3.
Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer.
N Engl J Med
; 381(4): 307-316, 2019 07 25.
Artículo
en Inglés
| MEDLINE | ID: mdl-31166679
4.
Apalutamide plus abiraterone acetate and prednisone versus placebo plus abiraterone and prednisone in metastatic, castration-resistant prostate cancer (ACIS): a randomised, placebo-controlled, double-blind, multinational, phase 3 study.
Lancet Oncol
; 22(11): 1541-1559, 2021 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-34600602
5.
Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial.
Lancet Oncol
; 19(7): 904-915, 2018 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-29804902
6.
Ombrabulin plus cisplatin versus placebo plus cisplatin in patients with advanced soft-tissue sarcomas after failure of anthracycline and ifosfamide chemotherapy: a randomised, double-blind, placebo-controlled, phase 3 trial.
Lancet Oncol
; 16(5): 531-40, 2015 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-25864104
7.
Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial.
Lancet Oncol
; 15(7): 700-12, 2014 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-24831977
8.
Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study.
Lancet Oncol
; 14(1): 38-47, 2013 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-23200175
9.
Quality of life in patients with advanced non-small-cell lung cancer given maintenance treatment with pemetrexed versus placebo (H3E-MC-JMEN): results from a randomised, double-blind, phase 3 study.
Lancet Oncol
; 13(3): 292-9, 2012 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-22336221
10.
Bempegaldesleukin Plus Nivolumab in Untreated Advanced Melanoma: The Open-Label, Phase III PIVOT IO 001 Trial Results.
J Clin Oncol
; 41(30): 4756-4767, 2023 10 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-37651676
11.
Correlation between work productivity loss and EORTC QLQ-C30 and -BR23 domains from the MONALEESA-7 trial of premenopausal women with HR+/HER2- advanced breast cancer.
Ther Adv Med Oncol
; 14: 17588359221081203, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-35251320
12.
Updated Overall Survival of Ribociclib plus Endocrine Therapy versus Endocrine Therapy Alone in Pre- and Perimenopausal Patients with HR+/HER2- Advanced Breast Cancer in MONALEESA-7: A Phase III Randomized Clinical Trial.
Clin Cancer Res
; 28(5): 851-859, 2022 Mar 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-34965945
13.
Genomic Profiling of Premenopausal HR+ and HER2- Metastatic Breast Cancer by Circulating Tumor DNA and Association of Genetic Alterations With Therapeutic Response to Endocrine Therapy and Ribociclib.
JCO Precis Oncol
; 52021.
Artículo
en Inglés
| MEDLINE | ID: mdl-34504990
14.
A phase 2 randomized clinical trial of abiraterone plus ADT, apalutamide, or abiraterone and apalutamide in patients with advanced prostate cancer with non-castrate testosterone levels (LACOG 0415).
Eur J Cancer
; 158: 63-71, 2021 Oct 13.
Artículo
en Inglés
| MEDLINE | ID: mdl-34655838
15.
Health-related quality of life in premenopausal women with hormone-receptor-positive, HER2-negative advanced breast cancer treated with ribociclib plus endocrine therapy: results from a phase III randomized clinical trial (MONALEESA-7).
Ther Adv Med Oncol
; 12: 1758835920943065, 2020.
Artículo
en Inglés
| MEDLINE | ID: mdl-32782490
16.
Real-World Molecular Testing and Treatment Patterns in Brazilian Patients with Newly Diagnosed Locally Advanced or Metastatic NSCLC.
Clinics (Sao Paulo)
; 75: e1777, 2020.
Artículo
en Inglés
| MEDLINE | ID: mdl-33084767
17.
Final Analysis of the Ipilimumab Versus Placebo Following Radiotherapy Phase III Trial in Postdocetaxel Metastatic Castration-resistant Prostate Cancer Identifies an Excess of Long-term Survivors.
Eur Urol
; 78(6): 822-830, 2020 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-32811715
18.
Nivolumab plus ipilimumab versus chemotherapy as first-line treatment in advanced non-small-cell lung cancer with high tumour mutational burden: patient-reported outcomes results from the randomised, open-label, phase III CheckMate 227 trial.
Eur J Cancer
; 116: 137-147, 2019 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-31195357
19.
Evaluation of quality of life in patients with metastatic colorectal cancer treated with capecitabine.
Clin Colorectal Cancer
; 7(2): 126-33, 2008 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-18501072
20.
Bevacizumab biosimilar BEVZ92 versus reference bevacizumab in combination with FOLFOX or FOLFIRI as first-line treatment for metastatic colorectal cancer: a multicentre, open-label, randomised controlled trial.
Lancet Gastroenterol Hepatol
; 3(12): 845-855, 2018 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-30262136